Purple Biotech Ltd (PPBT): Price and Financial Metrics
GET POWR RATINGS... FREE!
PPBT Stock Price Chart Interactive Chart >
PPBT Price/Volume Stats
| Current price | $2.87 | 52-week high | $6.75 |
| Prev. close | $3.06 | 52-week low | $2.44 |
| Day low | $2.73 | Volume | 124,500 |
| Day high | $2.98 | Avg. volume | 100,463 |
| 50-day MA | $3.30 | Dividend yield | N/A |
| 200-day MA | $3.82 | Market Cap | 74.45M |
Purple Biotech Ltd (PPBT) Company Bio
Purple Biotech Ltd operates as a pharmaceutical company. The Company discovers and develops medicines, drugs, and other pharmaceutical products for the treatment of osteoarthritis pain and hypertension. Purple Biotech serves customers globally.
Latest PPBT News From Around the Web
Below are the latest news stories about Purple Biotech Ltd that investors may wish to consider to help them evaluate PPBT as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning, trader! |
Could The Solid State plc (LON:SOLI) Ownership Structure Tell Us Something Useful?The big shareholder groups in Solid State plc ( LON:SOLI ) have power over the company. Insiders often own a large... |
Purple Biotech Reports Second Half and Full-Year 2021 Financial ResultsREHOVOT, Israel, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced financial results for the year and the six months ended December 31, 2021. “We achieved significant progress in the advancement of our promising oncology pipeline during this year with notable data releases in both |
Purple Biotech Issues Letter to ShareholdersREHOVOT, Israel, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, is pleased to issue the following letter from its Chief Executive Officer, Isaac Israel, to its shareholders. View as PDF Dear shareholders, I look back at 2021 proudly as a foundation-setting year for Purple Biotech, one with clin |
Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of DirectorsREHOVOT, Israel, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Ori Hershkovitz, a long-time life sciences industry investor, to its Board of Directors. “We are thrilled to welcome Ori to the Purple Biotech Board of Directors,” said Dr. Eric Rowinsky, Chairman |
PPBT Price Returns
| 1-mo | -2.71% |
| 3-mo | -1.71% |
| 6-mo | -27.71% |
| 1-year | -47.44% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -26.22% |
| 2021 | 2.10% |
| 2020 | -51.13% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...